Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 21, Number 6—June 2015
Research

Oral Cholera Vaccine Coverage, Barriers to Vaccination, and Adverse Events following Vaccination, Haiti, 20131

Rania A. TohmeComments to Author , Jeannot François, Kathleen Wannemuehler, Preetha Iyengar, Amber Dismer, Paul Adrien, Terri B. Hyde, Barbara J. Marston, Kashmira A. Date, Eric D. Mintz, and Mark A. Katz
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (R.A. Tohme, K. Wannemuehler, P. Iyengar, A. Dismer, T.B. Hyde, B.J. Marston, K. Date, E. Mintz); Ministry of Public Health and Population, Port-au-Prince, Haiti (J. Francois, P. Adrien); Centers for Disease Control and Prevention, Port-au-Prince (M.A. Katz)

Main Article

Table 3

Adverse events reported within 14 days of receipt of oral cholera vaccine, by area, Haiti, 2013*

Adverse event
Petite Anse, no. (%)
Cerca Carvajal, no. (%)
First dose
No. who received dose 768 691
Total events reported 68 (7.9; 95% CI 6.0–10.3) 56 (8.0; 95% CI 5.4–11.7)
Common events reported†
Nausea 20 (2.6) 17 (2.5)
Vertigo 15 (2.0) 11 (1.6)
Abdominal pain 13 (1.7) 17 (2.5)
Weakness/fatigue 11 (1.4) 4 (0.6)
Diarrhea 9 (1.2) 9 (1.3)
Vomiting 5 (0.7) 5 (0.7)
Bloating 3 (0.4) 7 (1.0)
Fever 8 (1.0) 5 (0.7)
Headache 2 (0.3) 4 (0.6)
Rash
4 (0.5)
Not reported
Second dose
No. who received dose 697 637
Total events reported 35 (4.7; 95% CI 3.0–7.3) 29 (4.1; 95% CI 2.4–6.8)
Common events reported‡
Vertigo 6 (0.9) 7 (1.1)
Nausea 7 (1.0) 5 (0.8)
Abdominal pain 6 (0.9) 9 (1.4)
Vomiting 1 (0.1) 2 (0.3)
Diarrhea 2 (0.3) 4 (0.6)
Fever 4 (0.6) 3 (0.5)
Weakness/fatigue 4 (0.6) 1 (0.2)
Headache 3 (0.4) 3 (0.5)
Rash 6 (0.9) Not reported
Bloating 2 (0.3) Not reported

*The categories for adverse events are not mutually exclusive as participants had the option to report multiple adverse events.
†Denominator incudes persons who received the first dose. Percentages are unweighted for the purpose of description only.
‡Denominator includes persons who received the second dose. Percentages are unweighted for the purpose of description only.

Main Article

1Results from this study were partially presented at the 49th US–Japan Conference on Cholera and Other Enteric Bacterial Infections; 2015 Jan 14–16; Gainesville, Florida, USA.

Page created: May 15, 2015
Page updated: May 15, 2015
Page reviewed: May 15, 2015
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external